407 Cabot Road
South San Francisco
32 articles with GigaGen
GigaGen Inc. will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson's presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif.
GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies
GigaGen Inc. today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID).
GigaGen Inc. announced that Sheila M. Keating, Ph.D., has joined the company as Director, Immunology.
GigaGen CEO David Johnson to Present on the Power of Surge Technology to Discover Unique Immuno-oncology Antibodies at 14th Annual PEGS Summit
GigaGen Inc. announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the discovery of unique and functional antibodies utilizing Surge technology at the 14th Annual PEGS Summit.
GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018
GigaGen, Inc. announced that David Johnson, Ph.D., chief executive officer, will present data from the company's proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018.
Dr. Simons will lead development of custom sequencing technology for antibody screening and immune function analysis
Natively Paired Antibodies Are Better: Study by GigaGen in Collaboration with Global Biopharmaceutical Company Describes Novel Approach to Identifying Antibodies with High Therapeutic Potential
GigaGen has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice.
GigaGen completed relocation to One Tower Place in late December 2017.
GigaGen today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline.
GigaGen Studies Published In Peer-Reviewed Journal mAbs, Validate Its Novel Monoclonal Antibody Discovery Approach In Mouse And Human Antibody Repertoires